PTC Therapeutics (NASDAQ:PTCT) VP Sells $194,912.77 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,813 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $69.29, for a total value of $194,912.77. Following the sale, the vice president owned 111,312 shares of the company’s stock, valued at $7,712,808.48. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Wednesday, February 18th, Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total value of $213,698.16.
• On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.93, for a total transaction of $180,330.02.
• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total transaction of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total transaction of $171,196.30.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT traded up $0.97 during mid-day trading on Thursday, reaching $69.90. The company had a trading volume of 976,090 shares, compared to its average volume of 1,253,063. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50. The stock has a market capitalization of $5.61 billion, a PE ratio of 8.17 and a beta of 0.48. The stock’s 50 day moving average is $75.12 and its 200-day moving average is $67.76.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.30). PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. On average, sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AlphaQuest LLC lifted its position in shares of PTC Therapeutics by 337.7% in the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after acquiring an additional 6,102 shares during the period. Vise Technologies Inc. acquired a new position in shares of PTC Therapeutics in the second quarter valued at $486,000. Prudential Financial Inc. lifted its position in PTC Therapeutics by 35.5% in the second quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company’s stock worth $4,115,000 after purchasing an additional 22,060 shares during the period. WCM Investment Management LLC bought a new position in PTC Therapeutics in the third quarter worth $8,919,000. Finally, Sector Gamma AS boosted its stake in PTC Therapeutics by 28.0% during the third quarter. Sector Gamma AS now owns 118,112 shares of the biopharmaceutical company’s stock worth $7,249,000 after buying an additional 25,862 shares in the last quarter.

Analysts Set New Price Targets

PTCT has been the topic of a number of research reports. Wells Fargo & Company increased their price objective on PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Royal Bank Of Canada cut shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their target price for the company from $82.00 to $91.00 in a research note on Monday, December 1st. Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $68.00 to $119.00 in a research note on Tuesday, January 27th. TD Cowen restated a “hold” rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $80.67.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.